PDCD1 and cancer: Peking University Cancer Hospital studied the changes in the flora of 74 GI tract tumor patients before and after treatment with immune checkpoint inhibitors and found that the composition of the patients’ body flora and gut microbial metabolites affect the patients’ response to programmed cell death protein 1/programmed cell death 1 ligand 1(PD1/PDL1) antibodies.